LSD, magic mushrooms, MDMA, ketamine, DMT… it’s a suspicious product line for a legitimate business — and psychedelics startups know it. With that in mind, it’s unsurprising that the sector are wary of the stereotypes around hallucinogens. “What the industry really needs is the most boring person in the room to be presenting the topic,” says Clara Burtenshaw, co-founder of Neo Kuma Ventures, Europe’s largest VC fund for psychedelic healthcare. It would be harsh to call Burtenshaw the most boring person in the room, but she’s not the clichéd lover of trips. More polished entrepreneur than kaleidoscopic hippy, Burtenshaw was…
Read Entire Article
